Biocom

Catch the most recent Group Purchasing Newsletter to learn more about how to safeguard your organization from a cyberattack with @centrexIT's Cyber Crisis Day After Report, @SunaSolutions' breakdown of the key phases of managed service provider deployment, @Dotcompliance_'s recently published case study outlining its process in replacing Codis' legacy systems with a unified cloud-based eQMS and more. Read the full edition: bit.ly/3TYRUgk

2026 Biocom Catalyst Award winner Sarah Allard of @UCSD Soil Health Center explores how microbial communities shape our world, from the human body to agricultural plants and soils. Read her story: bit.ly/4iK2gKj #BiocomCatalystAwards

Companies importing from overseas often tie up substantial capital in customs duties and fees, expenses which seem wasted when imported goods are later exported, returned or destroyed. However, in these specific situations, these duties may be recoverable. Join Biocom and @getpaxai on Tuesday, November 10, at 11 a.m. for a virtual introduction to duty drawback, an often forgotten method of recovering these funds. Designed for trade compliance, supply chain, finance, procurement and global operations leaders, this session will cover practical strategies to streamline the duty drawback process, identify tariff recovery opportunities and reclaim up to 99% of duties already paid. Register: bit.ly/4yLbrz6

This week in Bay Area life sciences: @GileadSciences reports positive Phase 2 SWIFT study results for emvistegrast for the treatment of ulcerative colitis. #IDEAYABiosciences and Servier present clinical trial data supporting darovasertib as a potential foundational therapy in the treatment of uveal melanoma. @RevMedicines doses the first patients in the Phase 3 RASolve 308 trial evaluating zoldonrasib in a first-line treatment of metastatic RAS G12D non-squamous non-small cell lung cancer. Subscribe to receive the next newsletter in your inbox: bit.ly/40rlR8a

The market has shifted. Has your capital strategy? Join us on November 4 for the next installment of our San Diego CFO series, where leaders from @Crinetics, @EYnews and #latigobiotherapeutics will examine IPO readiness, M&A, private capital and other paths to growth or liquidity. Don't miss this opportunity to explore what separates companies that are positioned to act from those that aren't and how leaders can preserve optionality in a rapidly changing market. Register: bit.ly/3WTrkWE Thank you to our sponsors: @DFINSolutions, @EYnews, @JLL, @jpmorgan. @Marsh_MMA, @SayvaSolutions and #Stout.

Last call: Applications for 1:1 meetings with Servier’s External Innovation Team close November 6. On December 9, Servier Pharmaceuticals will hold in-person partnering meetings in South San Francisco. Servier is seeking partners across four priority areas: 🔹 Oncology assets in CNS tumors, GI cancers and hematologic malignancies 🔹 Neurology programs in rare movement and neuromuscular disorders, refractory epilepsies and other rare neurological disorders 🔹 AI and digital technologies supporting R&D, clinical development, pharmaceutical operations and patient care 🔹 Enabling technologies spanning therapeutic platforms, drug delivery, advanced biological models, biomarkers, imaging and manufacturing Opportunities may include asset licensing, external research agreements and regionally focused partnerships. Applications close November 6, 11:59 p.m. PST: bit.ly/4zeeOiK

This week in San Diego life sciences: @FateThx presents updated preliminary data on FT819 for the treatment of active lupus nephritis. #ThaumatecTechGroup has expanded its offerings to provide end-to-end software services for medical devices, supporting medtech companies from initial development and regulatory compliance through postmarket maintenance and product evolution. @TravereRare presents new biomarker data suggesting FILSPARI may modify disease pathophysiology in IgA nephropathy. @ZentalisP reports median overall survival data in cyclin E1-positive, platinum-resistant ovarian cancer from DENALI Part 1b. Subscribe to receive the next newsletter in your inbox: bit.ly/4iqn5b1

2026 Biocom Catalyst Award winner Ioana Aanei of Scribe Therapeutics brings science, people and partners together to advance transformative medicines. Read her story: bit.ly/4yLcaAe #BiocomCatalystAwards

Thank you to our Greater LA CEO Summit steering committee for their dedication and guidance in shaping today’s conference. #BiocomCEOSummit

Bringing medical technology to market takes more than a breakthrough idea. Biocom helps medtech companies access capital, build partnerships, reduce costs and navigate industry challenges. Built for MedTech. Built for What’s Next. Explore membership: bit.ly/3Wwnzq1 #MedTech #LifeSciences

Our Greater LA CEO Summit is underway! Join the conversation and share your favorite moments by using #BiocomCEOSummit.

It's #NewMemberMonday! @BlueEvolution provides biological response screenings and analytical services to help agricultural biological-product developers understand how candidates perform and decide what to advance or test next. @darkskymedia develops endovascular technologies designed to make cerebral aneurysm treatments safer and more effective. @genselectai builds scientific reasoning AI models designed to learn continuously from real-world experiments and generate predictive causal theories. #GrannPharmaceuticals advances investigational mRNA lipid nanoparticle therapies that help cells produce missing proteins, with the goal of treating rare and genetic diseases. #OmnigeniQ creates physics-based micro world models that compute biological behavior from first principles to predict protein folding, molecular mechanisms and drug-target interactions. @Prendio_MA offers cloud-based procurement software that helps life science companies manage purchase approvals, vendors and ERP integration.

@BiocomInstitute is hosting a virtual volunteer information session for 2027 on Wednesday, November 4 at 12:00 p.m. PST. Attendees will learn about mentor expectation for the 2027 Fellowship Program, the flexible 15-hour time commitment and the direct impact mentors have on guiding early-career professionals into California’s life science sector. The discussion will also cover additional engagement opportunities, including resume reviews, mock interviews and career panels. This information session is designed for current and emerging leaders across all functional areas who are interested in supporting rising talent. Register here: bit.ly/4zdlOwD

We’re proud to announce the 2026 Biocom Catalyst Award winners! Meet 13 emerging life science leaders across San Diego, Greater LA and the Bay Area in LifeLines: bit.ly/4Bo3ceI. Follow along each week as we spotlight different winners and share their unique stories. #BiocomCatalystAwards

Last chance to register for our Greater LA CEO Summit. Don't miss this opportunity to gain valuable insights from industry leaders and connect with fellow life science CEOs. Register today: bit.ly/4yYuF51 #BiocomCEOSummit #LifeScienceEvents

Two down, one #BiocomCEOSummit to go! Our sincere thanks to our Bay Area CEO Summit steering committee for their wisdom and dedication in shaping today's incredible conference.

On October 28, Biocom president and CEO Tim Scott will speak at the inaugural Academic Consortium for Personalized RNA Therapies Workshop in Coronado, discussing pathways for first-in-human clinical trials of RNA therapeutics. Learn more: bit.ly/4dSK7qW

Discovery creates possibility. Manufacturing makes delivery possible. Biocom's Economic Impact Report found that California employed 143,572 life science manufacturing workers in 2025, accounting for 35.3% of the state’s life science jobs. Explore the report: bit.ly/4uXG7uN

This month in Greater Los Angeles life sciences: #AtaraBiotherapeutics reports that the FDA accepted its biologics license application for tab-cel®. @ImmunityBio receives expanded FDA approval for Anktiva in bladder cancer. #PasadenaBioCollaborativeIncubator receives a transformational building gift from the Morton La Kretz family. #TORLBioTherapeutics strengthens its leadership team with the recent appointments of its chief financial officer and chief medical officer. Subscribe to receive the next newsletter in your inbox: bit.ly/3WFbOLh